Menu
Menu
Prolight Diagnostics is carrying out the development together with leading technology developer, TTP, The Technology Partnership in Cambridge, UK. TTP currently has around 236 researchers and designers employed who work with several large life science companies.
Prolight Diagnostics is carrying out the development together with leading technology developer, TTP, The Technology Partnership in Cambridge, UK. TTP currently has around 236 researchers and designers employed who work with several large life science companies. The technical partnership with TTP is an important aspect of Prolight Diagnostics’ development work, and ensures high quality according to international standards. Prolight Diagnostics has contributed to the development of the well-proven ELISA technology into a microformat, which has been combined with the Flex membrane technology, developed by TTP.
The further developed combination of these two technologies, PLD Micro Flex, has the potential to achieve equivalent test performance as hospital laboratories, as well as high flexibility and mobility.
– TTP is a leading technology development business based near Cambridge, UK. Our 236 strong team work with cutting edge companies all over the world, bringing advanced technologies to market. We are delighted to be partnering with Prolight to commercialise such a groundbreaking diagnostic product.
Matthew Carr, TTP Head of Life Science
Prolight Diagnostics utvecklar tillsammans med dotterbolaget Psyros Diagnostics samt teknologipartners innovativa, flexibla, patientnära testsystem, Point Of Care Testing (POCT) som är baserad på patenterad teknik. POC-tester utförs utanför det traditionella sjukhuslaboratoriet med små mobila instrument på exempelvis vårdcentraler, äldreboende, akutmottagningar och intensivvårdsavdelningar, vilket möjliggör testning nära patienten och med snabba provsvar. Denna teknik kommer att innebära att vården i ett tidigt diagnosskede kan skilja ut de patienter som snabbt behöver vård från de patienter som exempelvis inte har hjärtinfarkt. Försäljningsvärdet inom POCT området uppgick 2021 till USD 34,6 miljarder och är i stark tillväxt. Bolagets aktier handlas under kortnamnet PRLD på marknadsplatsen NGM Nordic SME.
info@prolightdiagnostics.se
Gasverksgatan 3A
222 29 Lund (Sweden)
Tel: +46(0)73 582 39 87